Related Experiment Videos
[Specific and substitute markers of hepatitis C in screening donor blood]
Insights
Testing donor blood for hepatitis C virus (HCV) antibodies using enzyme immunoassays (EIA) significantly reduces transmission risk. Second-generation EIA kits offer higher sensitivity for effective blood screening and diagnosis.
Area of Science:
- Hepatology and Virology
- Immunology and Serological Diagnostics
Context:
- Blood donation screening is critical for preventing transfusion-transmitted infections.
- Hepatitis C virus (HCV) poses a significant risk in blood transfusions.
- Evaluating diagnostic markers for HCV in donor populations is essential.
Purpose:
- To compare the efficacy of specific and substitute markers for hepatitis C detection in blood donors.
- To assess the impact of enzyme immunoassays (EIA) for anti-HCV antibody detection on transfusion safety.
- To determine the optimal testing strategies for HCV in blood donation settings.
Summary:
- A study of 2615 blood donors utilized two EIA kits to detect HCV antibodies and non-specific markers of non-A, non-B hepatitis.
- 1.3% of donors tested positive for HCV antibodies, highlighting the need for mandatory EIA testing.
- Second-generation EIA kits are recommended for their sensitivity in blood screening, while specific tests aid in diagnosis and treatment monitoring.
Impact:
- Implementing EIA testing for anti-HCV antibodies can reduce the risk of virus transmission via blood components by threefold.
- Compulsory HCV screening for medical staff is proposed to mitigate occupational exposure risks.
- This study underscores the need for refined diagnostic criteria and preventive strategies for HCV infection.
Abstract:
The efficacy of specific and substitute markers of hepatitis C was compared in donor blood screening. 2615 blood donors were examined using two EIA kits for detection of HCV antibodies. The presence of nonspecific markers of non-A non-B hepatitis was also checked. 1.3% of the donors were found to carry HCV antibodies. This necessitates donor blood testing for anti-HCV antibodies using EIA. Such measure reduces three-fold the risk of the virus transmission with blood components and preparations. The preference should be given to more sensitive test systems of the second generation, whereas less sensitive, but more specific, test systems are more valuable for accurate diagnosis and treatment effects assessment in HCV infection. It would be appropriate to perform compulsory examinations for HCV infection in medical staff. This will entail efforts on development of the infection diagnostic verification criteria and preventive measures.